Pfizer Inc. (PFE)
- Previous Close
26.00 - Open
26.00 - Bid --
- Ask --
- Day's Range
25.92 - 26.50 - 52 Week Range
25.23 - 40.37 - Volume
35,582,503 - Avg. Volume
42,881,541 - Market Cap (intraday)
148.698B - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
70.97 - EPS (TTM)
0.37 - Earnings Date May 1, 2024
- Forward Dividend & Yield 1.68 (6.40%)
- Ex-Dividend Date Jan 25, 2024
- 1y Target Est
31.10
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
www.pfizer.com88,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PFE
Performance Overview: PFE
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PFE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PFE
Valuation Measures
Market Cap
148.70B
Enterprise Value
206.85B
Trailing P/E
70.97
Forward P/E
11.85
PEG Ratio (5yr expected)
0.26
Price/Sales (ttm)
2.53
Price/Book (mrq)
1.67
Enterprise Value/Revenue
3.54
Enterprise Value/EBITDA
21.64
Financial Highlights
Profitability and Income Statement
Profit Margin
3.62%
Return on Assets (ttm)
1.55%
Return on Equity (ttm)
2.35%
Revenue (ttm)
58.5B
Net Income Avi to Common (ttm)
2.13B
Diluted EPS (ttm)
0.37
Balance Sheet and Cash Flow
Total Cash (mrq)
12.69B
Total Debt/Equity (mrq)
84.37%
Levered Free Cash Flow (ttm)
1.02B
Research Analysis: PFE
Company Insights: PFE
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: PFE
Technical Assessment: Neutral in the Intermediate-Term
The stock market is in a rough patch for the first time since the July to October period of last year. After the major indices hit their secondary highs on April 11 (the Nasdaq hit its all-time high that day), is has pretty much been "down periscope." Out of those trading six days, the S&P 500 (SPX), Nasdaq, and Nasdaq 100 (QQQ) have fallen between 0.9% and 2.1% on three (SPX) or four of those days. Despite the very steep downside slope of the Big 3, NYSE breadth actually bottomed on April 12 and 15, illustrating that the selling has been concentrated in Big Tech and the many stocks that were overly extended on a momentum basis.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, European interest-rate cuts on the horizon; firm opportunities among drug and biopharma firms; and reports Tesla's affordable vehicle will be canceled; and Lazard, PVH, and Genmab.
Large Cap US Pick List - April 2024
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Technical Assessment: Neutral in the Intermediate-Term
Was that a case of quarter-end buying by institutions? Over the last 50 minutes of the trading session on Wednesday, the S&P 500 (SPX) took off like a rocket, surging 30 points and finishing 0.9% higher on the day and at another all-time high. But the biggest winners on the day were small-caps, with the Russell 2000 (IWM) surging 2.2% and the S&P 600 (SML) spiking 2.4%. The IWM is breaking out of a more-than two-year base and closed at its highest level since December 2021.